Coya Therapeutics (COYA) Liabilities and Shareholders Equity (2021 - 2026)

Coya Therapeutics (COYA) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $53.3 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 38.71% year-over-year to $53.3 million; the trailing twelve-month figure through Mar 2026 stood at $168.7 million (up 6.62% YoY), and the FY2025 full-year result was $50.0 million, up 12.63% from the prior year.
• Liabilities and Shareholders Equity advanced to $53.3 million in Q1 2026, from $50.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $53.3 million in Q1 2026 to a low of $8.4 million in Q4 2022.
• A 5-year average of $32.7 million and a median of $36.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity surged 391.48% in 2023 and slipped 16.24% in 2025, its largest moves.
• Tracing COYA's Liabilities and Shareholders Equity over 5 years: stood at $8.4 million in 2022, then surged by 391.48% to $41.3 million in 2023, then increased by 7.48% to $44.3 million in 2024, then climbed by 12.63% to $50.0 million in 2025, then climbed by 6.65% to $53.3 million in 2026.
• Business Quant data shows COYA's Liabilities and Shareholders Equity at $53.3 million in Q1 2026, $50.0 million in Q4 2025, and $32.0 million in Q3 2025.